id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-N-2267-0001,FDA,FDA-2020-N-2267,"Endo Pharmaceuticals, Inc.; Withdrawal of Approval of a New Drug Application for OPANA (Oxymorphone Hydrochloride) Extended-Release Tablets",Notice,Withdrawal,2020-12-23T05:00:00Z,2020,12,2020-12-23T05:00:00Z,,2020-12-23T15:11:29Z,2020-28283,0,0,09000064849c0fe7